Printer Friendly

HYAL ANNOUNCES PATENT DEVELOPMENTS

 HYAL ANNOUNCES PATENT DEVELOPMENTS
 MISSISSAUGA, Ont., Aug. 25 /PRNewswire/ -- Hyal Pharmaceutical


Corporation announced today important progress in the process of obtaining patent approval for its exclusively licensed hyaluronic acid drug delivery technology. Via the release of the International Preliminary Examination Report dated Aug. 14, 1992, the Company has been notified that the two independent claims and therefore the 86 claims presented for examination in the patent applications entitled, "Treatments of Conditions and Disease" are all to be considered as strictly novel and inventive. Novelty is an essential criteria for patentability and the report stated that the applicant had shown with numerous examples at claimed dosages, that hyaluronic acid can increase the activity of many drugs by facilitating their uptake, and that this result would not have been expected by a man skilled in the art based on the formulations in the sighted prior art, and was therefore novel.
 Copies of the International Preliminary Examination Report will now be filed with the appropriate authorities in each of the countries and regions in which this patent application has been filed, including; Canada, U.S.A., Europe, Japan, Australia, Brazil, North and South Korea, Finland, and Norway. While the report is not binding, the conclusions reached by the examiner are considered to be an important step in obtaining approvals of the patent application in countries in which it has been filed, and should significantly enhance Hyal's ability to obtain the maximum possible patent protection for the invention.
 Hyal is a Canadian company dedicated to the development and commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronic Acid drug delivery technology.
 Hyal Pharmaceutical Corporation
 TSE Symbol HPC
 -0- 8/25/92
 /CONTACT: Dr. Samuel S. Asculai, president & CEO, 416-366-4863; or, David Harper, vice president Development 416-366-4863, both of Hyal Pharmaceutical/
 (HPC.) CO: Hyal Pharmaceutical Corporation ST: Ontario IN: MTC SU:


LR -- NY014 -- 2890 08/25/92 08:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 25, 1992
Words:314
Previous Article:STI TO ACQUIRE GREAT AMERICAN LIFE INSURANCE COMPANY FOR $470 MILLION
Next Article:NATIONAL COMPUTER SYSTEMS, INC. ANNOUNCES QUARTERLY CASH DIVIDEND
Topics:


Related Articles
HYAL PHARMACEUTICAL REPORTS HIGH EFFICACY LEVELS FROM FIRST PHASE III TRIAL
HYAL'S NEW AND UNEXPECTED MECHANISM FOR PAIN RELIEF
HYAL PHARMACEUTICAL PROVIDES DEVELOPMENT UPDATE AT SPROTT HEALTH CARE CONFERENCE
HYAL ANNOUNCES SECOND PHASE III CLINICAL TRIAL FOR TOPICAL PAIN PRODUCT
HYAL ANNOUNCES ITS FIRST PHASE III CLINICAL TRIAL FOR INJECTABLE, INTRAVENOUS PAIN PRODUCT ALL LEAD PRODUCTS NOW IN PHASE III
DRUGS TARGETED TO CANCER TUMORS BY HYAL'S DRUG DELIVERY TECHNOLOGY
POTENTIAL FOR HYAL PRODUCTS IN HEART DISEASE: PREVENTION OF RESTENOSIS TARGETED BY HYAL'S DRUG DELIVERY TECHNOLOGY
CLINICAL COMPARISON DEMONSTRATES HYANALGESE-D HAS THE EDGE OVER VOLTAREN EMULGEL IN RELIEVING ARTHRITIS PAIN
Hyal Reports Phase III Results From Its Hyanalgese-D(TM) Clinical Trial
Hyal & Shire Announce Phase III Results of HyClinda(TM)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters